These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
227 related articles for article (PubMed ID: 9021207)
1. In vitro evaluation of a novel ketolide antimicrobial agent, RU-64004. Jamjian C; Biedenbach DJ; Jones RN Antimicrob Agents Chemother; 1997 Feb; 41(2):454-9. PubMed ID: 9021207 [TBL] [Abstract][Full Text] [Related]
2. Antimicrobial activity of RU-66647, a new ketolide. Jones RN; Biedenbach DJ Diagn Microbiol Infect Dis; 1997; 27(1-2):7-12. PubMed ID: 9127099 [TBL] [Abstract][Full Text] [Related]
3. In vitro activities of two ketolides, HMR 3647 and HMR 3004, against gram-positive bacteria. Malathum K; Coque TM; Singh KV; Murray BE Antimicrob Agents Chemother; 1999 Apr; 43(4):930-6. PubMed ID: 10103202 [TBL] [Abstract][Full Text] [Related]
4. In vitro activity of RU 64004, a new ketolide antibiotic, against gram-positive bacteria. Schülin T; Wennersten CB; Moellering RC; Eliopoulos GM Antimicrob Agents Chemother; 1997 May; 41(5):1196-202. PubMed ID: 9145901 [TBL] [Abstract][Full Text] [Related]
5. Comparative antimicrobial activity of ABT-773, a novel ketolide, tested against drug-resistant Gram-positive cocci and Haemophilus influenzae. Rospide MF; Biedenbach DJ; Jones RN Int J Antimicrob Agents; 2001 Jun; 17(6):451-5. PubMed ID: 11397614 [TBL] [Abstract][Full Text] [Related]
6. Antimicrobial activity of quinupristin-dalfopristin (RP 59500, Synercid) tested against over 28,000 recent clinical isolates from 200 medical centers in the United States and Canada. Jones RN; Ballow CH; Biedenbach DJ; Deinhart JA; Schentag JJ Diagn Microbiol Infect Dis; 1998 Jul; 31(3):437-51. PubMed ID: 9635235 [TBL] [Abstract][Full Text] [Related]
7. Comparison of in vitro activities of ABT-773 and telithromycin against macrolide-susceptible and -resistant streptococci and staphylococci. Shortridge VD; Zhong P; Cao Z; Beyer JM; Almer LS; Ramer NC; Doktor SZ; Flamm RK Antimicrob Agents Chemother; 2002 Mar; 46(3):783-6. PubMed ID: 11850262 [TBL] [Abstract][Full Text] [Related]
8. Antimicrobial characterisation of CEM-101 activity against respiratory tract pathogens, including multidrug-resistant pneumococcal serogroup 19A isolates. Farrell DJ; Sader HS; Castanheira M; Biedenbach DJ; Rhomberg PR; Jones RN Int J Antimicrob Agents; 2010 Jun; 35(6):537-43. PubMed ID: 20211548 [TBL] [Abstract][Full Text] [Related]
9. Comparative in-vitro activity of ketolide HMR 3647 and four macrolides against gram-positive cocci of known erythromycin susceptibility status. Hamilton-Miller JM; Shah S J Antimicrob Chemother; 1998 Jun; 41(6):649-53. PubMed ID: 9687104 [TBL] [Abstract][Full Text] [Related]
10. In-vitro activity of the new ketolide antibiotic HMR 3647 against gram-positive bacteria. Schülin T; Wennersten CB; Moellering RC; Eliopoulos GM J Antimicrob Chemother; 1998 Sep; 42(3):297-301. PubMed ID: 9786468 [TBL] [Abstract][Full Text] [Related]
11. In vitro activities of the ketolide HMR 3647 against recent gram-positive clinical isolates and Haemophilus influenzae. Barry AL; Fuchs PC; Brown SD Antimicrob Agents Chemother; 1998 Aug; 42(8):2138-40. PubMed ID: 9687424 [TBL] [Abstract][Full Text] [Related]
12. In vitro antimicrobial activity and MIC quality control guidelines of RPR 106972 (RPR 112808/RPR106950): a novel orally administered streptogramin combination. The Quality Control Study Group. Putnam SD; Jones RN; Johnson DM Diagn Microbiol Infect Dis; 1997 Jul; 28(3):139-47. PubMed ID: 9294704 [TBL] [Abstract][Full Text] [Related]
13. Susceptibilities of 228 penicillin- and erythromycin-susceptible and -resistant pneumococci to RU 64004, a new ketolide, compared with susceptibilities to 16 other agents. Ednie LM; Spangler SK; Jacobs MR; Appelbaum PC Antimicrob Agents Chemother; 1997 May; 41(5):1033-6. PubMed ID: 9145864 [TBL] [Abstract][Full Text] [Related]
14. Antipneumococcal activities of a ketolide (HMR 3647), a streptogramin (quinupristin-dalfopristin), a macrolide (erythromycin), and a lincosamide (clindamycin). Barry AL; Fuchs PC; Brown SD Antimicrob Agents Chemother; 1998 Apr; 42(4):945-6. PubMed ID: 9559816 [TBL] [Abstract][Full Text] [Related]
15. Antianaerobic activity of the ketolide RU 64004 compared to activities of four macrolides, five beta-lactams, clindamycin, and metronidazole. Ednie LM; Spangler SK; Jacobs MR; Appelbaum PC Antimicrob Agents Chemother; 1997 May; 41(5):1037-41. PubMed ID: 9145865 [TBL] [Abstract][Full Text] [Related]
16. Epidemiologic trends in nosocomial and community-acquired infections due to antibiotic-resistant gram-positive bacteria: the role of streptogramins and other newer compounds. Jones RN; Low DE; Pfaller MA Diagn Microbiol Infect Dis; 1999 Feb; 33(2):101-12. PubMed ID: 10091033 [TBL] [Abstract][Full Text] [Related]
17. In vitro activity of ABT773, a new ketolide derivative exhibiting innovative microbiological properties against well-characterised antibiotic resistant pathogens in Italy. Bozzolasco M; Debbia EA; Roveta S; Schito AM; Marchese A Int J Antimicrob Agents; 2004 Jan; 23(1):11-6. PubMed ID: 14732308 [TBL] [Abstract][Full Text] [Related]
18. Comparative antimicrobial activity and kill-curve investigations of novel ketolide antimicrobial agents (HMR 3004 and HMR 3647) tested against Haemophilus influenzae and Moraxella catarrhalis strains. Biedenbach DJ; Barrett MS; Jones RN Diagn Microbiol Infect Dis; 1998 Jun; 31(2):349-53. PubMed ID: 9635909 [TBL] [Abstract][Full Text] [Related]
20. Antimicrobial spectrum and potency of dalbavancin tested against clinical isolates from Europe and North America (2003): initial results from an international surveillance protocol. Jones RN; Fritsche TR; Sader HS; Goldstein BP J Chemother; 2005 Dec; 17(6):593-600. PubMed ID: 16433188 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]